These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 22023666)

  • 21. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
    Azzouni F; Abu samra K
    J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
    Vardi M; Nini A
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erectile dysfunction.
    Katz A; Katz A
    CMAJ; 2010 Mar; 182(4):381-2. PubMed ID: 20142374
    [No Abstract]   [Full Text] [Related]  

  • 28. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
    Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
    BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.
    Schneider T; Gleissner J; Merfort F; Hermanns M; Beneke M; Ulbrich E
    J Sex Med; 2011 Oct; 8(10):2904-11. PubMed ID: 21771281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
    Shaeer O
    J Sex Med; 2013 Feb; 10(2):532-40. PubMed ID: 23088586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of ED under the "severe distress" criteria in the NHS: a real-life study.
    Mohee A; Bretsztajn L; Storey A; Eardley I
    J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of ED: PDE-5 Inhibitors.
    Shabsigh R
    Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
    Chung E
    J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
    Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
    J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
    Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.
    Harv Health Lett; 2004 Jan; 29(3):3. PubMed ID: 14734283
    [No Abstract]   [Full Text] [Related]  

  • 38. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
    Chivers ML; Rosen RC
    J Sex Med; 2010 Feb; 7(2 Pt 2):858-72. PubMed ID: 19929916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
    Kloner RA
    Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.